Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for MDA5-positive clinically amyopathic dermatomyositis with interstitial lung disease
ChiCTR1800016629Phase 4Recruiting
- Sponsor
- Renji Hospital
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tofacitinib in amyopathic dermatomyositis (ADM) and interstitial lung disease (ILD) (2 arms), sponsored by Renji Hospital. Primary endpoints: overall survival and 12-month overall survival. Started Jul 2017; status: recruiting.
02
Drugs
03
Conditions
amyopathic dermatomyositis (ADM)interstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR1800016629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016629.